NCT01746901 - A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

August 9, 2013

Study Completion Date

August 9, 2013

Conditions

Healthy

Interventions

DRUG

Placebo

Placebo solution + Placebo ALO-02 (intact)

DRUG

intact ALO-02 60 mg/7.2 mg

Placebo solution + ALO-02 60 mg/7.2 mg (intact)

DRUG

crushed ALO-02 60 mg/7.2 mg

crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)

DRUG

crushed oxycodone IR 60 mg

crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)

DRUG

crushed ALO-02 40 mg/4.8 mg

crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)

DRUG

crushed oxycodone IR 40 mg

crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)

Trial Locations (1)

INC Research Toronto, Inc., Toronto